Obesity and thyroid cancer: Epidemiologic associations and underlying mechanisms

Obesity Reviews

Volumn 14, Issue 12, 2013, Pages 1006-1022

  Pazaitou Panayiotou, K ^a   Polyzos, S A ^b   Mantzoros, C S ^c  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Insulin resistance; Obesity; Thyroid cancer

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ESTROGEN; INSULIN; LEPTIN; SOMATOMEDIN C; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR; THYROXINE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL;

CANCER RISK; CARCINOGENESIS; COMORBIDITY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDEMIC GOITER; ENDOTHELIAL DYSFUNCTION; FREE THYROXINE INDEX; GLUCOSE BLOOD LEVEL; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; HYPOADIPONECTINEMIA; INFLAMMATORY CELL; INSULIN RESISTANCE; LIPID METABOLISM; LYMPH NODE METASTASIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; PROTEIN EXPRESSION; REVIEW; THYROID CANCER; THYROID CARCINOMA; THYROID CELL; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY; TRIACYLGLYCEROL BLOOD LEVEL;

INSULIN RESISTANCE; OBESITY; THYROID CANCER;

ADIPOKINES; ADIPOSE TISSUE; COMORBIDITY; FEMALE; HUMANS; MALE; OBESITY; RISK FACTORS; THYROID NEOPLASMS;

EID: 84887612511     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12070     Document Type: Review

References (126)

1. Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest 2012; 35(6 Suppl.): 3-9.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295: 2164-2167.
3. Davies L, Ouellette M, Hunter M, Welch HG. The increasing incidence of small thyroid cancers: where are the cases coming from? Laryngoscope 2010; 120: 2446-2451.
4. Alevizaki M, Papageorgiou G, Rentziou G etal. Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental. Thyroid 2009; 19: 749-754.
5. Polyzos SA, Kita M, Avramidis A. Thyroid nodules - stepwise diagnosis and management. Hormones (Athens) 2007; 6: 101-119.
6. Gomez Segovia I, Gallowitsch HJ, Kresnik E etal. Descriptive epidemiology of thyroid carcinoma in Carinthia, Austria: 1984-2001. Histopathologic features and tumor classification of 734 cases under elevated general iodination of table salt since 1990: population-based age-stratified analysis on thyroid carcinoma incidence. Thyroid 2004; 14: 277-286.
7. Enewold L, Zhu K, Ron E etal. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18: 784-791.
8. Pazaitou-Panayiotou K, Iliadou PK, Chrisoulidou A etal. The increase in thyroid cancer incidence is not only due to papillary microcarcinomas: a 40-year study in 1.778 patients. Exp Clin Endocrinol Diabetes 2013; 121: 397-401.
9. Mangano JJ. Geographic variation in U.S. thyroid cancer incidence and a cluster near nuclear reactors in New Jersey, New York, and Pennsylvania. Int J Health Serv 2009; 39: 643-661.
10. How J, Tabah R. Explaining the increasing incidence of differentiated thyroid cancer. CMAJ 2007; 177: 1383-1384.
11. Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol 2010; 6: 363-370.
12. Kim HJ, Kim NK, Choi JH etal. Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf) 2013; 78: 134-140.
13. Leitzmann MF, Brenner A, Moore SC etal. Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer 2010; 126: 2947-2956.
14. Cléro E, Leux C, Brindel P etal. Pooled analysis of two case-control studies in New Caledonia and French Polynesia of body mass index and differentiated thyroid cancer: the importance of body surface area. Thyroid 2010; 20: 1285-1293.
15. Aschebrook-Kilfoy B, Sabra MN, Brenner A etal. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study. Thyroid 2011; 21: 957-963.
16. Mijovic T, How J, Payne RJ. Obesity and thyroid cancer. Front Biosci(Schol Ed) 2011; 3: 555-564.
17. Zhao ZG, Guo XG, Ba CX etal. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res 2012; 40: 2041-2050.
18. Shih SR, Chiu WY, Chang TC, Tseng CH. Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res 2012; 2012: 578285.
19. Wolk A, Gridley G, Svensson M etal. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.
20. Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord 2009; 7: 279-287.
21. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta analysis of prospective observational studies. Lancet 2008; 371: 569-578.
22. Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord 2009; 7: 375-380.
23. Mechanick JI, Camacho PM, Cobin RH etal.; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines - 2010 update. Endocr Pract 2010; 16: 270-283.
24. Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 1987; 79: 1-12.
25. Dal Maso L, La Vecchia C, Franceschi S etal. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 2000; 11: 137-144.
26. Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 2001; 93: 745-750.
27. Mack W, Preston-Martin S, Bernstein L, Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol 2002; 12: 395-401.
28. Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004; 15: 35-43.
29. Boru C, Silecchia G, Pecchia A etal. Prevalence of cancer in Italian obese patients referred for bariatric surgery. Obes Surg 2005; 15: 1171-1176.
30. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-4754.
31. Engeland A, Tretli S, Akslen LA, Bjørge T. Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer 2006; 95: 366-370.
32. Brindel P, Doyon F, Rachedi F etal. Anthropometric factors in differentiated thyroid cancer in French Polynesia: a case-control study. Cancer Causes Control 2009; 20: 581-590.
33. Kitahara CM, Platz EA, Freeman LE etal. Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev 2011; 20: 464-472.
34. Rinaldi S, Lise M, Clavel-Chapelon F etal. Body size and risk of differentiated thyroid carcinomas: findings from the EPIC study. Int J Cancer 2012; 131: E1004-E1014.
35. Almquist M, Johansen D, Björge T etal. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project (Me-Can). Cancer Causes Control 2011; 22: 743-751.
36. Peterson E, De P, Nutall R. BMI, diet and female reproductive factors as risks for thyroid cancer: a systematic review. PLoS ONE 2012; 7: e29177.
37. Bosetti C, Kolonel L, Negri E etal. A pooled analysis of case-control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control 2001; 12: 375-382.
38. Bosetti C, Negri E, Colonel L etal. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). Cancer Causes Control 2002; 13: 765-775.
39. Lee S, Park S, Lee CR etal. The impact of body habitus on the surgical outcomes of transaxillary single-incision robotic thyroidectomy in papillary thyroid carcinoma patients. Surg Endosc 2013; 27: 2407-2414.
40. Kitahara CM, Platz EA, Beane Freeman LE etal. Physical activity, diabetes, and thyroid cancer risk: a pooled analysis of five prospective studies. Cancer Causes Control 2012; 23: 463-471.
41. Borena W, Stocks T, Jonsson H etal. Serum triglycerides and cancer risk in the Metabolic syndrome and Cancer (Me-Can) collaborative study. Cancer Causes Control 2011; 22: 291-299.
42. Stocks T, Rapp K, Biorge T etal. Blood glucose and risk of incident and fatal cancer in the Metabolic syndrome and Cancer project (Me-Can): analysis of six prospective cohorts. PLoS Med 2009; 6: e1000201.
43. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 93: 194-202.
44. Tulinius H, Sigfússon N, Sigvaldason H, Bjarnadóttir K, Tryggvadóttir L. Risk factors for malignant diseases: a cohort study on a population of 22, 946 Icelanders. Cancer Epidemiol Biomarkers Prev 1997; 6: 863-873.
45. Rapp K, Schroeder J, Klenk J etal. Fasting blood glucose and cancer risk in a cohort of more than 140, 000 adults in Austria. Diabetologia 2006; 49: 945-952.
46. Deleu S, Pirson I, Coulonval K etal. IGF-1 or insulin, and the TSH cyclic AMP cascade separately control dog and human thyroid cell growth and DNA synthesis, and complement each other in inducing mitogenesis. Mol Cell Endocrinol 1999; 149: 41-51.
47. Van Keymeulen A, Dumont JE, Roger PP. TSH induces insulin receptors that mediate insulin costimulation of growth in normal human thyroid cells. Biochem Biophys Res Commun 2000; 279: 202-207.
48. Dumont JE, Lamy F, Roger P, Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 1992; 72: 667-697.
49. Milazzo G, La Rosa GL, Catalfamo R, Vigneri R, Belfiore A. Effect of TSH in human thyroid cells: evidence for both mitogenic and antimitogenic effects. J Cell Biochem 1992; 49: 231-238.
50. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9: 299-314.
51. Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010; 17: 3449-3461.
52. Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol 2010; 321: 94-102.
53. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
54. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
55. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15: 1069-1074.
56. Okayasu I. The relationship of lymphocytic thyroiditis to the development of thyroid carcinoma. Endocr Pathol 1997; 8: 225-230.
57. Antonaci A, Consorti F, Mardente S, Giovannone G. Clinical and biological relationship between chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Oncol Res 2009; 17: 495-503.
58. Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011; 96: 3615-3627.
59. Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: a century later. Adv Anat Pathol 2012; 19: 181-186.
60. Graff-Baker A, Sosa JA, Roman SA. Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment. Curr Opin Oncol 2010; 22: 17-22.
61. Muzza M, Degl'Innocenti D, Colombo C etal. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 2010; 72: 702-708.
62. Proietti A, Ugolini C, Melillo RM etal. Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters. Thyroid 2011; 21: 1209-1215.
63. Hagström J, Heikkilä A, Siironen P etal. TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma. J Clin Pathol 2012; 65: 333-338.
64. Rezzonico J, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid 2008; 18: 461-464.
65. Yasar HY, Ertuǧrul O, Ertuǧrul B, Ertuǧrul D, Sahin M. Insulin resistance in nodular thyroid disease. Endocr Res 2011; 36: 167-174.
66. Anil C, Akkurt A, Ayturk S, Kut A, Gursoy A. Impaired glucose metabolism is a risk factor for increased thyroid volume and nodule prevalence in a mild-to-moderate iodine deficient area. Metabolism 2013; 62: 970-975.
67. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. Endocr Relat Cancer 2012; 19: F1-F8.
68. Braun S, Bitton-Worms K, LeRoith D. The link between the metabolic syndrome and cancer. Int J Biol Sci 2011; 7: 1003-1015.
69. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995; 16: 117-142.
70. Vella V, Sciacca L, Pandini G etal. The IGF system in thyroid cancer: new concepts. Clin Pathol Mol Pathol 2001; 54: 121-125.
71. Belfiore A, Pandini G, Vella V etal. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochemie 1999; 81: 403-417.
72. Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol 2009; 161: 599-605.
73. Rendina D, De Filippo G, Mossetti G etal. Relationship between metabolic syndrome and multinodular non-toxic goiter in an inpatient population from a geographic area with moderate iodine deficiency. J Endocrinol Invest 2012; 35: 407-412.
74. Rezzónico J, Rezzónico M, Pusiol E, Pitoia F, Niepomniszcze H. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2011; 9: 69-75.
75. Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol 1992; 15: 273-276.
76. Frittitta L, Sciacca L, Catalfamo R etal. Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis? Cancer 1999; 85: 492-498.
77. Myal Y, Shiu RP, Bhaumick B, Bala M. Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 1984; 44: 5486-5490.
78. Siegel G, Tomer Y. Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature. Endocr Res 2005; 3: 51-58.
79. Liu YJ, Qiang W, Liu XJ etal. Association of insulin-like growth factor-1 with thyroid nodules. Oncol Lett 2011; 2: 1297-1301.
80. Mitsiades N, Pazaitou-Panayiotou K, Aronis KN etal. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab 2011; 96: 2023-2028.
81. Völzke H, Friedrich N, Schipf S etal. Association between serum insulin-like growth factor-I levels and thyroid disorders in a population-based study. J Clin Endocrinol Metab 2007; 92: 4039-4045.
82. Ruchala M, Skiba A, Gurgul E, Uruski P, Wasko R, Sowinski J. The occurrence of thyroid focal lesions and a need for fine needle aspiration biopsy in patients with acromegaly due to an increased risk of thyroid cancer. J Neuro Endocrinol Lett 2009; 30: 382-386.
83. Anagnostis P, Efstathiadou ZA, Polyzos SA etal. Acromegaly: presentation, morbidity and treatment outcomes at a single centre. Int J Clin Pract 2011; 65: 896-902.
84. Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front Biosci 2011; 16: 1634-1650.
85. Mantzoros CS, Moschos SJ. Leptin: in search of role(s) in human physiology and pathophysiology. Clin Endocrinol (Oxf) 1998; 49: 551-567.
86. Uddin S, Bavi P, Siraj AK etal. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer 2010; 17: 191-202.
87. Cheng SP, Yin PH, Hsu YC etal. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep 2011; 26: 1265-1271.
88. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Regulation of leptin receptor expression in human papillary thyroid cancer cells. Biomed Pharmacother 2012; 66: 469-473.
89. Hsieh CJ, Wang PW, Wang ST etal. Serum leptin concentrations of patients with sequential thyroid function changes. Clin Endocrinol (Oxf) 2002; 57: 29-34.
90. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A. Leptin levels in thyroid cancer. Asian J Surg 2009; 32: 216-223.
91. Hedayati M, Yaghmaei P, Pooyamanesh Z, Zarif Yeganeh M, Hoghooghi Rad L. Leptin: a correlated peptide to papillary thyroid carcinoma? J Thyroid Res 2011; 2011: 832163.
92. Cheng SP, Chi CW, Tzen CY etal. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010; 147: 847-853.
93. Zhang GA, Hou S, Han S, Zhou J, Wang X, Cui W. Clinicopathological implications of leptin and leptin receptor expression in papillary thyroid cancer. Oncol Lett 2013; 5: 797-800.
94. Polyzos SA. Editorial: adiponectin in health and disease: current evidence and therapeutic perspectives. Curr Med Chem 2012; 19: 5425-5426.
95. Lin SY, Huang SC, Sheu WH. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal. Metabolism 2010; 59: 195-199.
96. Park JT, Yoo TH, Chang TI etal. Insulin resistance and lower plasma adiponectin increase malignancy risk in nondiabetic continuous ambulatory peritoneal dialysis patients. Metabolism 2011; 60: 121-126.
97. Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Expression and biologic significance of adiponectin receptors in papillary thyroid carcinoma. Cell Biochem Biophys 2013; 65: 203-210.
98. Roger PP, Dumont JE. Thyrotropin is a potent growth factor for normal human thyroid cells in primary culture. Biochem Biophys Res Commun 1987; 149: 707-711.
99. Carayon P, Thomas-Morvan C, Castanas E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 1980; 51: 915-920.
100. Chang TC, Kuo SH, Liaw KY, Chang CC, Chen FW. Cell kinetics, DNA content and TSH receptor-adenylate cyclase system in differentiated thyroid cancer. Clin Endocrinol (Oxf) 1988; 29: 477-484.
101. Goldberg RC, Lindsay S, Nichols CW, ChaikoV IL. Induction of neoplasms in thyroid glands of rats by subtotal thyroidectomy and by the injection of one microcurie of I-131. Cancer Res 1964; 24: 35-43.
102. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, JaViol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81: 4318-4323.
103. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91: 4295-4301.
104. Polyzos SA, Kita M, Efstathiadou Z etal. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol 2008; 134: 953-960.
105. Haymart MR, Repplinger DJ, Leverson GE etal. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Clin Endocrinol Metab 2008; 93: 809-814.
106. Jonklaas J, Nsouli-Maktabi H, Soldin SJ. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid 2008; 18: 943-952.
107. Fiore E, Rago T, Provenzale MA etal. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer 2009; 16: 1251-1260.
108. McLeod DS, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012; 97: 2682-2692.
109. Sari R, Balci MK, Altunbas H, Karayalcin U. The effect of body weight and weight loss on thyroid volume and function in obese women. Clin Endocrinol (Oxf) 2003; 59: 258-262.
110. Michalaki MA, Vagenakis AG, Leonardou AS etal. Thyroid function in humans with morbid obesity. Thyroid 2006; 16: 73-78.
111. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012; 19: 408-413.
112. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N. SEER Cancer Statistics Review, 1975-2006. 2012. [WWW document]. URL http://seer.cancer.gov/csr/1975_2006/ (accessed 2012).
113. Chen G, Vlantis AC, Zeng Q, van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets 2008; 8: 367-377.
114. Freeman EW, Sammel MD, Lin H, Gracia CR. Obesity and reproductive hormone levels in the transition to menopause. Menopause 2010; 17: 718-726.
115. Kansakar E, Chang YJ, Mehrabi M, Mittal V. Expression of estrogen receptor, progesterone receptor, and vascular endothelial growth factor-A in thyroid cancer. Am Surg 2009; 75: 785-789; discussion 789.
116. Lee ML, Chen GG, Vlantis AC, Tse GMK, Leung BCH, van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J 2005; 11: 113-121.
117. Kumar A, Klinge CM, Goldstein RE. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int J Oncol 2010; 36: 1067-1080.
118. Magri F, Capelli V, Rotondi M etal. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk. Endocr Relat Cancer 2012; 19: 463-471.
119. Navarro Silvera SA, Miller AB, Rohan TE. Risk factors for thyroid cancer: a prospective cohort study. Int J Cancer 2005; 1: 433-438.
120. Akslen LA, Nilssen S, Kvåle G. Reproductive factors and risk of thyroid cancer. A prospective study of 63, 090 women from Norway. Br J Cancer 1992; 65: 772-774.
121. Horn-Ross PL, Canchola AJ, Ma H, Reynolds P, Bernstein L. Hormonal factors and the risk of papillary thyroid cancer in the California teachers study cohort. Cancer Epidemiol Biomarkers Prev 2011; 20: 1751-1759.
122. Negri E, Dal Maso L, Ron E etal. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 1999; 10: 143-155.
123. La Vecchia C, Ron E, Franceschi S etal. A pooled analysis of case-control studies of thyroid cancer III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999; 10: 157-166.
124. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33: 547-594.
125. Lee DH, Huang H, Choi K, Mantzoros C, Kim YB. Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice. Am J Physiol Endocrinol Metab 2012; 302: E552-E560.
126. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326.